Tenax Therapeutics (TENX) Stock Price, News & Analysis

Company Overview

Tenax Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions. The company conducts preclinical and clinical studies under the guidance of U.S. Food and Drug Administration regulations and is advancing its most advanced candidates toward pivotal trials.

Headquartered in Exton, Pennsylvania, Tenax Therapeutics serves hospitals, surgery centers and other healthcare facilities primarily in North America. The company collaborates with academic institutions and strategic partners to advance its pipeline. Tenax is managed by a team of executives with backgrounds in pharmaceutical development and commercialization, and it is publicly traded on the NASDAQ under the ticker symbol TENX.

Key Stats

• Today's Range: $13.65 to $15.52
• 50-Day Range: $10.54 to $18.32
• 52-Week Range: $5.78 to $19.40
• Volume: 1.78 million shs
• Average Volume: 1.27 million shs
• Market Capitalization: $363.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.67
• Consensus Rating: Moderate Buy

Tenax Therapeutics Stock Analysis - MarketRank™

Tenax Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 351st out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Tenax Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Tenax Therapeutics has a consensus price target of $37.67, representing about 174.9% upside from its current price of $13.70.

Amount of Analyst Coverage

Tenax Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tenax Therapeutics are expected to grow in the coming year, from ($1.48) to ($1.43) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tenax Therapeutics is -9.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tenax Therapeutics is -9.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tenax Therapeutics has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.65% of the float of Tenax Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tenax Therapeutics has a short interest ratio ("days to cover") of 1.37, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tenax Therapeutics has recently increased by 14.46%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tenax Therapeutics does not currently pay a dividend.

Dividend Growth

Tenax Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.69

News Sentiment

Tenax Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Tenax Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 5 people have searched for TENX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Tenax Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tenax Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.81% of the stock of Tenax Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

1.67% of the stock of Tenax Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 7/31/2026
• Today: 8/01/2026
• Next Earnings (Estimated): 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:TENX
• CIK: 34956
• Web: www.tenaxthera.com
• Phone: 919-855-2100
• Fax: 919-855-2133
• Employees: 9
• Year Founded: 1967

Price Target and Rating

• Average Price Target for Tenax Therapeutics: $37.67
• High Price Target: $50.00
• Low Price Target: $27.00
• Potential Upside/Downside: +174.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$52.60 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -56.32%
• Return on Assets: -53.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.52
• Quick Ratio: 14.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.42 per share
• Price / Book: 1.31

Miscellaneous

• Outstanding Shares: 26,525,000
• Free Float: 23,658,000
• Market Cap: $363.39 million
• Optionable: Not Optionable
• Beta: 0.92